

## Urinary incontinence (update) and pelvic organ prolapse in women: management

### Review questions

*NICE guideline tbc*

*Review questions*

*August 2018*

*Early submission*

*Evidence reviews were developed by  
National Guideline Alliance hosted by the  
Royal College of Obstetricians and  
Gynaecologists*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2019. All rights reserved. Subject to [Notice of Rights](#).

ISBN:

## Contents

<b>Review questions .....</b>	<b>5</b>
-------------------------------	----------

## Review questions

Question number	Chapter	Review questions
1.1	A	What is the value of urodynamic assessment in addition to clinical assessment before primary surgery for stress urinary incontinence?
2.1	B	How often, by whom and should alternative treatment options be reviewed for women who are using absorbent containment products?
3.1	C	What are the risks to cognitive function for women taking anticholinergic drugs for overactive bladder?
4.1	D	What is the value of urodynamic assessment before botulinum toxin type A treatment?
4.2	D	What is the most effective initial dose of botulinum toxin type A for treating overactive bladder?
5.1	E	What is the most effective surgical management of stress urinary incontinence, including mesh and non-mesh procedures?
5.2	E	What is the effectiveness of surgical management of stress urinary incontinence (including mesh and non-mesh procedures), compared to pelvic floor muscle training?
6.1	F	What is the effectiveness of multidisciplinary teams of various compositions for the assessment and management of simple and complex cases of urinary incontinence or pelvic organ prolapse, including mesh complications?
7.1	G	What is the most effective strategy for assessing pelvic organ prolapse?
8.1	H	What lifestyle interventions are effective for managing pelvic organ prolapse?
8.2	H	What is the effectiveness of topical oestrogen for managing pelvic organ prolapse with vaginal atrophy?
8.3	H	What are the most effective conservative management options (for example, pelvic floor exercises and pessaries) for pelvic organ prolapse?
8.4	I	What are the most effective surgical management options (including mesh and non-mesh procedures) for pelvic organ prolapse?
8.5	I	What is the role of surgery to prevent postoperative urinary incontinence in women having surgery for pelvic organ prolapse, including the sequence of interventions?
8.6	I	What are the effectiveness of surgical options for pelvic organ prolapse, compared to pessaries?
9.1	J	What is the most effective surgical management for women with both stress urinary incontinence and pelvic organ prolapse, including the sequence of interventions?
10.1	K	What is the most effective strategy for assessing mesh complications of sexual dysfunction; pain; vaginal, urinary and bowel complications after mesh surgery?
11.1	L	What are the most effective management options for vaginal complications (including exposure, extrusion, erosion and infection) after mesh surgery?
11.2	L	What are the most effective management options for sexual dysfunction after mesh surgery?
11.3	L	What are the most effective management options for pain after mesh surgery?
11.4	L	What are the most effective management options for urinary complications after mesh surgery?
11.5	L	What are the most effective management options for bowel symptoms after mesh surgery?